· Pharma · Pharma Desk
ASC35 enters Phase I as one of the first long-acting dual incretin candidates aimed at monthly dosing. A pipeline read against tirzepatide, retatrutide, orforglipron, and MariTide on mechanism, dosing interval, and adherence implications.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.